Skip to main content
Premium Trial:

Request an Annual Quote

LION Licenses New EST Clustering Software to Intervet: Mar 6, 2001 (rev. 1)

NEW YORK, March 6 – Lion Bioscience has licensed its soon-to-be launched EST clustering analysis software everEST, as well as genomeScout, its genome analysis software, to the Netherlands-based animal health company Intervet International, Lion said Tuesday.

The company has also extended licenses to Intervet for its SRS data integration platform and its bioScout genomic annotation system.

“Intervet is a valuable customer with a broad experience in bioinformatics,” Christian Marcazzo, Lion’s director of product marketing, told GenomeWeb.

Lion said this new extended software licensing agreement will provide additional revenue, but Marcazzo declined to comment on its financial terms.

Intervet is the second company to license and implement everEST. Lion has also installed the software, which it will officially launch this spring, at Nestle.

EverEST is designed to retrieve data from Lion’s SRS platform and perform EST clustering on it. “For the first time, the user can retrieve biological information concerning ESTs and EST consensus sequences from all major biological databases,” Marcazzo said. “Built-in applications can be launched to further analyze consensus sequences, such as BLAST or LION's annotation application bioScout.”

To perform the EST clustering in everEST Lion obtained a non-exclusive license to the StackPack clustering engine from Electric Genetics in South Africa last fall.

StackPack includes data management and visualization tools that enable researchers to rapidly cluster, align and analyze high volumes of ESTs and partial-length sequences. They highlight variations in transcripts and can accelerate gene discovery, gene function analysis, expression analysis and drug development.

Lion has established partnerships with a number of Life Science companies, including Aventis, Bayer, Boehringer Ingelheim, Celera, DuPont, GlaxoSmithkline, Janssen, Merck, Nestle, Novartis, Paradigm Genetics, Pharmacia & Upjohn, Sumitomo Pharmaceuticals, and Tripos. SRS is currently used by more than 30 life science organizations to integrate more than 400 different databases, the company said.
The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.